New pharmacological targets and treatments for atrial fibrillation

Trends in Pharmacological Sciences

Volumn 31, Issue 8, 2010, Pages 364-371

  Carlsson, Leif ^a   Duker, Göran ^a   Jacobson, Ingemar ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2' (4 METHOXYPHENYLACETAMIDOMETHYL) N [2 (3 PYRIDYL)ETHYL] 2 BIPHENYLCARBOXAMIDE; 4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; AMIODARONE; ANTIARRHYTHMIC AGENT; AZD 1305; BUDIODARONE; CALCIUM; CONNEXIN 40; CONNEXIN 43; CONNEXIN 45; DELAYED RECTIFIER POTASSIUM CHANNEL; DRONEDARONE; FG 3019; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; NTC 801; OMEGA 3 FATTY ACID; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; RANOLAZINE; ROTIGAPTIDE; RYANODINE RECEPTOR; SODIUM CHANNEL BLOCKING AGENT; TEPRENONE; TERTIAPIN Q; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VERNAKALANT; XEN D 0101;

CALCIUM TRANSPORT; CHANNEL GATING; CLINICAL TRIAL; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GAP JUNCTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM;

EID: 77955270889     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2010.05.001     Document Type: Review

References (73)

1. Fuster, V. et al. (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur. Heart J. 27, 1979-2030.
2. Wyse D.G., et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 2002, 347:1825-1833.
3. Roy D., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 2008, 358:2667-2677.
4. Nattel S., Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat. Rev. Drug Discov. 2006, 5:1034-1049.
5. Burashnikov A., Antzelevitch C. New pharmacological strategies for the treatment of atrial fibrillation. Ann. Noninvasive Electrocardiol. 2009, 14:290-300.
6. Dobrev D., Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010, 375:1212-1223.
7. Wijfels M.C., et al. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995, 92:1954-1968.
8. Nattel S., et al. Arrhythmogenic ion-channel remodelling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol. Rev. 2007, 87:425-456.
9. Nattel S., et al. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ. Arrhythm. Electrophysiol. 2008, 1:62-73.
10. Olson T.M., et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 2006, 15:2185-2191.
11. Bilodeau M.T., Trotter B.W. Kv1.5 blockers for the treatment of atrial fibrillation: approaches to optimization of potency and selectivity and translation to in vivo pharmacology. Curr. Top. Med. Chem. 2009, 9:436-451.
12. Tamargo J., et al. IKur/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin. Investig. Drugs 2008, 18:399-416.
13. Ford J.W., Milnes J.T. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): rationale, pharmacology and evidence for potential therapeutic value. J. Cardiovasc. Pharmacol. 2008, 52:105-120.
14. Blaauw Y., et al. Early class III drugs for the treatment of atrial fibrillation. Efficacy and atrial selectivity of AVE0118 in remodelled atria of the goat. Circulation 2004, 110:1717-1724.
15. Gögelein H., et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:183-192.
16. Voigt N., et al. Inhibition of IK, ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:251-259.
17. Dobrzynski H., et al. Distribution of the muscarinic K+ channel proteins Kir3.1 and Kir3.4 in the ventricle, atrium, and sinoatrial node of the heart. J. Histochem. Cytochem. 2001, 49:1221-1234.
18. Dobrev D., et al. The G protein-gated potassium current IKACh is constitutively active in patients with chronic atrial fibrillation. Circulation 2005, 112:3697-3706.
19. Cha T.J., et al. Kir3-based inward rectifier potassium current. Potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006, 113:1730-1737.
20. Ehrlich J.R., Nattel S. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?. Curr. Opin. Cardiol. 2008, 24:50-55.
21. Altomare C., et al. Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. Br. J. Pharmacol. 2000, 130:1315-1320.
22. Inomata N., et al. Mechanisms of the anticholinergic effect of SUN 1165 in comparison with flecainide, disopyramide and quinidine in single atrial myocyte isolated from guinea-pig. Br. J. Pharmacol. 1991, 104:1007-1011.
23. + channel blockers: insights from mathematical models and experimental correlates. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H1489-H1504.
24. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 1989, 321:406-412. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators.
25. Burashnikov A., et al. Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation. Ann. N. Y. Acad. Sci. 2008, 1123:105-112.
26. Burashnikov A., et al. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation. Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
27. Fedida D. Vernakalant (RSD1235): a novel atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 2007, 16:519-532.
28. Burashnikov A., et al. AZD1305 exerts atrial-predominant electrophysiological actions and is effective in suppressing and inhibiting reinduction of atrial fibrillation in the dog. J. Cardiovasc. Pharmacol. 2010, 10.1097/FJC.0b013e3181e0bc6b.
29. 2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:195-206.
30. Antoons G., Sipido K. Targeting calcium handling in arrhythmias. Europace 2008, 10:1364-1369.
31. Blayney L.M., Lai F.A. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol. Ther. 2009, 123:151-177.
32. Vest J.A., et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005, 111:2025-2032.
33. Sood S., et al. Intracellular calcium leak due to FKBP12.6 deficiency in mice facilitates the inducibility of atrial fibrillation. Heart Rhythm 2008, 5:1047-1054.
34. Kumagai K., et al. Antiarrhythmic effects of JVT519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J. Cardiovasc. Electrophysiol. 2003, 14:880-884.
35. Fauconnier J., et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1559-1564.
36. Shaw R.M., Rudy Y. Ionic mechanisms of propagation in cardiac tissue: roles of sodium- and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ. Res. 1997, 81:727-741.
37. Dhein S., et al. Improving cardiac gap junction communication as a new antiarrhythmic mechanism: the action of antiarrhythmic peptides. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:221-234.
38. Beardsley M.A., et al. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ. Res. 2000, 87:656-662.
39. Xing D., et al. ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. J. Cardiovasc. Electrophysiol. 2003, 14:510-520.
40. Shiroshita-Takeshita A., et al. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmics peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 2007, 115:310-318.
41. Butera J.A., et al. Discovery of (2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid hydrochloride (GAP-134), an orally active small molecule gap-junction modifier for the treatment of atrial fibrillation. J. Med. Chem. 2009, 52:908-911.
42. Rossman E.I., et al. The gap junction modifier, GAP-134 (2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid), improves conduction and reduced atrial fibrillation/flutter in the sterile pericarditis model. J. Pharmacol. Exp. Ther. 2009, 329:1127-1133.
43. Smit M.D., van Gelder I.C. Upstream therapy of atrial fibrillation. Expert Rev. Cardiovasc. Ther. 2009, 7:763-778.
44. Savelieva I., et al. Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance. Naunyn Schmiedebergs Arch. Pharmacol. 2010, 381:207-219.
45. Dorian P., Singh B.N. Upstream therapies to prevent atrial fibrillation. Eur. Heart J. 2008, 10(Suppl. H):H11-H31.
46. 2+ channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs. Circulation 1999, 100:2191-2197.
47. Ohashi N., et al. A comparison between calcium channel blocking drugs with different potencies for T- and L-type channels in preventing atrial electrical remodeling. J. Cardiovasc. Pharmacol. 2004, 44:386-392.
48. Shinagawa K., et al. Effects of antiarrhythmics drugs on fibrillation in the remodeled atrium. Insights into the mechanism of the superior efficacy of amiodarone. Circulation 2003, 107:1440-1446.
49. 2+ currents in compensated hypertrophy and heart failure. Cardiovasc. Res. 1998, 37:300-311.
50. Quignard J.F., et al. Properties and modulation of Ca channels in adult human atrial cells. J. Clin. Invest. 1997, 99:185-193.
51. Healey J.S., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol. 2005, 45:1832-1839.
52. Madrid A.H., et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331-336.
53. Kumagai K., et al. Effect of angiotensin II type I receptor antagonism on electrical and structural remodelling in atrial fibrillation. J. Am. Coll. Cardiol. 2003, 41:2197-2204.
54. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 2009, 360:1606-1617. The GISSI-AF Investigators.
55. Patti G., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation 2006, 114:1455-1461.
56. Korantzopoulus P., et al. Anti-inflammatory and antioxidant action of statins may favorably affect atrial remodeling in atrial fibrillation. Am. J. Cardiol. 2004, 93:1200.
57. Lijnen P.J., et al. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol. Genet. Metab. 2000, 71:418-435.
58. Sakata Y., et al. Transforming growth factor-β receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res. Cardiol. 2008, 103:60-68.
59. Brundel B.J., et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ. Res. 2006, 99:1394-1402.
60. Tahahashi N., et al. Induction of heat shock proteins prevents the arrhythmogenic substrate for atrial fibrillation. Int. J. Hyperthermia 2009, 25:641-646.
61. Camm A.J., Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J. Interv. Card. Electrophysiol. 2008, 23:7-14.
62. Roy D., et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation 2008, 117:1518-1525.
63. Torp-Pedersen C., et al. Oral vernakalant for the prevention of atrial fibrillation recurrence post-cardioversion. Eur. Heart J. 2009, 30:450.
64. Morey T.E., et al. Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J. Pharmacol. Exp. Ther. 2001, 297:260-266.
65. Arya A., et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 2009, 11:458-464.
66. Hoy S.M., Keam S.J. Dronedarone. Drugs 2009, 69:1647-1663.
67. Singh B.N., et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med. 2007, 357:987-999.
68. Davy J.M., et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am. Heart J. 2008, 156:527.e1-527.e9.
69. Køber L., et al. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med. 2008, 358:2678-2687.
70. Patel C., et al. Dronedarone. Circulation 2009, 120:636-644.
71. Zimetbaum P.J. Dronedarone for atrial fibrillation - an odyssey. N. Engl. J. Med. 2009, 360:1811-1813.
72. Hohnloser S.H., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 2009, 360:668-678.
73. Singh D., et al. Dronedarone for atrial fibrillation. Have we expanded the antiarrhythmic armamentarium?. J. Am. Coll. Cardiol. 2010, 55:1569-1576.